Volume 135, Issue 6, Pages 1953-1960 (December 2008) A Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial of Etanercept in the Treatment of Alcoholic Hepatitis Nicholas C. Boetticher, Craig J. Peine, Paul Kwo, Gary A. Abrams, Tushar Patel, Bashar Aqel, Lisa Boardman, Gregory J. Gores, William S. Harmsen, Craig J. McClain, Patrick S. Kamath, Vijay H. Shah Gastroenterology Volume 135, Issue 6, Pages 1953-1960 (December 2008) DOI: 10.1053/j.gastro.2008.08.057 Copyright © 2008 AGA Institute Terms and Conditions
Figure 1 Flow diagram. Flow of participants through each stage of the trial is shown. Gastroenterology 2008 135, 1953-1960DOI: (10.1053/j.gastro.2008.08.057) Copyright © 2008 AGA Institute Terms and Conditions
Figure 2 Kaplan–Meier survival analysis. Thirty-day mortality (vertical hashed line) was not significantly different between placebo (solid line) and etanercept (hashed line) groups. Six-month mortality rate was significantly higher in the etanercept arm compared with the placebo arm (P < .05). Gastroenterology 2008 135, 1953-1960DOI: (10.1053/j.gastro.2008.08.057) Copyright © 2008 AGA Institute Terms and Conditions